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Accepted 1 November 2012AbstractThere needs to be clarification on eligibility requirements and procedure standardization with regard to the therapeutic role of lymphade-
nectomy. If this is not done, consensus on the role of lymphadenectomy will not be reached. Although pelvic lymphadenectomy is not necessary
for patients with low-risk Stage I endometrial cancer, it has been suggested that combined pelvic and para-aortic lymphadenectomy is useful for
patients with intermediate-/high-risk endometrial cancer. Therefore, the therapeutic role of lymphadenectomy should be continuously evaluated.
If such a study is planned, it should not include patients with low risk of nodal metastasis, and one experimental arm of the study should assess
combined pelvic and para-aortic lymphadenectomy (fundamentally including the area above the inferior mesenteric artery and the renal vein). It
is necessary to establish a pre-operative risk assessment for nodal metastasis and procedural classification of lymphadenectomy. Some pre-
operative risk assessments for nodal metastasis have been proposed from Asian countries. The extent of the surgical field is defined as the
pelvic area alone, or combined pelvic and para-aortic area. The thoroughness of removal can be split into removal of only suspicious nodes,
selective dissection, or systematic dissection. Although randomized controlled trials provide the highest level of clinical evidence, special
difficulties are presented in randomized surgical trials. Nonentry of surgeons is a threat to external validity. The role of observational studies,
especially prospective cohort studies should be reconsidered when assessing the therapeutic significance of lymphadenectomy.
Copyright  2013, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Endometrial cancer is one of the most common malig-
nancies of the female genital tract, and its incidence in the
industrialized world has been increasing. The number of new
cases annually has increased in the United States, with 36,100
in 2000 [1] and 47,130 in 2012 [2]. The number of deaths
annually has also increased, with 6500 in 2000 [1] and 8010 in
2012 [2]. Eventually, one out of six patients with endometrial
cancer relapse and die of the disease. However, the FIGO
annual report has demonstrated that survival rates from* Corresponding author. Division of Gynecologic Oncology, National Hos-
pital Organization, Hokkaido Cancer Center, 4-2 Kikusui, Shiroishi-ku, Sap-
poro 003-0804, Japan.
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http://dx.doi.org/10.1016/j.tjog.2013.01.003endometrial cancer have been increasing in recent decades [3].
This trend even applies to cases with Stage IIIc endometrial
cancer. From this, physicians face two issues. Firstly, they
have to treat the largest number of patients ever and conse-
quently reduce the time required for treatment in one patient.
Secondly, improvements are needed in the treatment of pa-
tients with a high-risk prognosis. They need to make in-
terventions, including pre-operative risk assessment, surgical
procedures, and follow-up programs, more efficient.
As two randomized controlled trials (RCTs) from European
countries showed negative results of lymphadenectomy on
prognosis [4,5], many gynecologists have since declared at
conferences that standard surgery for endometrial cancer does
not include lymphadenectomy. However, this conclusion is
due to overgeneralization of the results of the randomized
studies. Surgery has been playing the leading part in thecs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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digm shift, except for the introduction of lymphadenectomy. It
is possible that many patients with endometrial cancer have
benefited from lymphadenectomy. The consistent increase in
survival rates may be due to it. In this article, we review the
results of two RCTs and one retrospective cohort analysis and
discuss the interpretation and limitations of randomized sur-
gical trials. We also discuss whether lymphadenectomy should
be recommended in the treatment of endometrial cancer. In
addition, we propose a group of patients who need lympha-
denectomy and a pre-operative assessment for predicting
lymph node metastasis.
Therapeutic role of lymphadenectomy: Previous
discussion
Before 2008, all studies regarding the role of lymphade-
nectomy in endometrial cancer were retrospective. Some
studies supported a survival benefit of lymphadenectomy
[6e13] and others did not [14e17]. Assessing nodal status is
necessary for determining the stage of the endometrial cancer.
However, there was no description of a procedure for this,
which caused confusion on the clinical scene. The most ac-
curate method to detect lymph node metastasis consisted of
systematically removing regional lymph nodes and inspecting
the specimens. Another method consisted of only palpating
lymph nodes or selectively removing only enlarged nodes. The
type and extent of lymph node dissection would vary greatly
across the surgical field.
In 2008, Benedetti-Panici et al in Italy reported results from
the first RCT (CONSORT trial) to assess the therapeutic effect
of lymphadenectomy [4]. In 2009, results from the second
RCT to assess the therapeutic role of lymphadenectomy were
published by the ASTEC study group [5]. The results of both
RCTs were, in particular, characterized by the unexpected
finding that the survival period in the nonlymphadenectomy
group was longer than in the lymphadenectomy group. In
addition, they showed that lymphadenectomy increased post-
operative complications. Therefore, many physicians have
since declared at medical meetings that standard surgery for
endometrial cancer should not include lymphadenectomy.
However, a lot of criticism of this idea has also been voiced.
The problem criticized most is that implementation of para-
aortic lymphadenectomy was at the discretion of the
attending physicians and only a small number of patients
underwent para-aortic lymphadenectomy (CONSORT trial:
26%, ASTEC trial: data not available). As a result, the median
number of lymph nodes removed was less than that in the
Japanese SEPAL study (CONSORT trial: 30; ASTEC trial: 14;
SEPAL study: 82) [4,5,18]. Another criticism is that lympha-
denectomy is used at a low frequency in European countries,
probably due to skepticism about its therapeutic role and
constraints based on their guidelines. According to the Euro-
pean Society for Medical Oncology (ESMO) guidelines, sur-
gical treatment in Stage I endometrial cancer does not always
include lymphadenectomy and surgical treatment in Stage II
endometrial cancer includes pelvic lymphadenectomy but notalways para-aortic lymphadenectomy [19]. It has been re-
ported that lymphadenectomy for endometrial cancer was
performed routinely in only 17e24% of centers in Europe
[20,21]. However, 98% of institutions used routine pelvic
lymph node dissection, and 93% of institutions used routine or
selective surgical treatment of para-aortic lymph nodes in
Japan [22]. It was described in that report that para-aortic
dissection/biopsy was used either routinely (12%) or selec-
tively based on tumor-related factors (81%).The fact that
lymphadenectomy used in the experimental arms of the two
RCTs was limited to pelvic lymph nodes means that surgery
commonly performed in Europe did not include para-aortic
lymphadenectomy. Therefore, many attending surgeons may
be reluctant to perform lymphadenectomy, especially in the
para-aortic area. Thus, it is possible that surgeries performed
in the two RCTs has inadequate level of surgery to demon-
strate the full benefit of lymphadenectomy.
Considering these limitations, appropriate interpretation of
both trials would be that pelvic lymphadenectomy does not
have therapeutic significance for low-risk clinical Stage I
endometrial cancer. As clinical Stage I includes not only low-
risk patients, but also intermediate- and high-risk patients,
concluding that pelvic lymphadenectomy does not have
therapeutic significance for clinical Stage I endometrial can-
cer will cause patients with intermediate- and high-risk fea-
tures to miss an opportunity to undergo lymphadenectomy. If
lymphadenectomy has survival benefits for intermediate and
high-risk cases, they would not be able to receive optimal
treatment.
In 2010, we presented results from the Survival Effect of
Para-aortic Lymphadenectomy (SEPAL) study, which showed
no survival benefit from combined pelvic and para-aortic
lymphadenectomy over pelvic lymphadenectomy alone for
low-risk patients, and significant survival benefits from
implementation of para-aortic lymphadenectomy in addition
to pelvic lymphadenectomy for intermediate- and high-risk
patients [18]. In that study, 36 lymph nodes were harvested
in the pelvic lymphadenectomy group and 82 in the combined
pelvic and para-aortic lymphadenectomy group. Surgery with
para-aortic lymphadenectomy was associated with decreased
death in patients with a hazard ratio of 0$44 (95%
CI ¼ 0.30e0.64, p < 0.0001) compared with surgery without
para-aortic lymphadenectomy. The combined pelvic and para-
aortic lymphadenectomy showed a 10.6% increase in the
5-year overall survival compared with that from pelvic lym-
phadenectomy alone in intermediate-/high-risk patients
(Table 1). In addition, the study demonstrated that para-aortic
lymphadenectomy improved survival rates independently from
the efficacy of any adjuvant treatment.
Considering previous results from retrospective and
prospective studies, standard primary surgery in low-risk
endometrial cancer includes hysterectomy and bilateral
salpingo-oophorectomy, but does not include lymphadenec-
tomy. However, a therapeutic role for lymphadenectomy
should be continuously assessed in intermediate-/high-risk
endometrial cancer, as combined pelvic and para-aortic lym-
phadenectomy might have survival benefits. However, such a
Table 1
Clinical studies regarding the therapeutic significance of lymphadenectomy in endometrial cancer.
CONSORT trial ASTEC trial SEPAL study
Jornal J Natl Cancer Inst (2008) Lancet (2009) Lancet (2010)
Study design prospective randomized
controlled study
prospective randomized
controlled study
retrospective comparative
cohort study
Participating hospital (n) 31 85 2
Eligibility Clinical stage I Clinical stage I Clinical stage I-III/operable stage IV
Cases (n) 514 1408 671
FIGO (1988) stage Stage I: 75% Stage I: 79% Stage I: 65%
Stage II: 8% Stage II: 13% Stage II: 10%
Stage III-IV: 15% Stage III-IV: 7% Stage III-IV: 25%
Unknown: 2% Unknown: 1% Unknown: 0%
Intervention LNX-: n ¼ 250 LNX-: n ¼ 704 PLX: n ¼ 325
LNX+: n ¼ 264 LNX+: n ¼ 704 PLX+PALX: n ¼ 346
Adjuvant treatment LNX-: RT 25%, CT 10% LNX-: RT 33%, CT 4% PLX: RT 23%, CT 27%
LNX+: RT 17%, CT 14% LNX+: RT 33%, CT 4% PLX+PALX: RT 1%, CT 47%
The number of LN removed (median) LNX-: 0 LNX-: 0 PLX: 34
LNX+: 30 LNX+: 14 PLX+PALX: 8
5-year overall survival LNX-: 90% LNX-: 81% PLX: L 94%, I/H 73%*
LNX+: 86% LNX+: 80% PLX+PALX: L 96%, I/H 83% *
5-year disease free survival LNX-: 82% LNX-: 79% PLX: L 93%, I/H 65%**
LNX+: 81% LNX+: 73% PLX+PALX: L 95%, I/H 81%**
Follow-up period 49 months 37 months 92 months
LN ¼ lymph node; LNX ¼ lymphadenectomy; PLX ¼ pelvic lymphadenectomy; PALX ¼ para-aortic lymphadenectomy; RT ¼ radiation therapy;
CT ¼ chemotherapy; L ¼ nbsp;low-risk (less than half myoinvasion, Grade 1/2, no lymphovascular space invasion); I ¼ intermediate-risk (other than low-risk and
high-risk); H ¼ high-risk (extrauterine disease). * p ¼ 0.0009, ** p < 0.0001.
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assessment. Although postoperative risk assessment is useful
for deciding whether adjuvant therapy should be conducted, it
is not useful when deciding what kind of surgery should be
performed. Pre-operative risk assessment is needed to decide
the type of surgery. This issue will be discussed in the
following section.
The first prerequisite for clinical trials to assess the
therapeutic role of lymphadenectomy: Preoperative risk
assessment for nodal metastasis
When the therapeutic effect of lymphadenectomy in
endometrial cancer is assessed, patients with low risk of
lymph node metastasis should not be included. However,
there has been no consensus for identifying the low-risk
group for nodal metastasis. Gynecologic Oncology Group
study number 33 (GOG #33) showed that there was no case
with nodal metastasis in the low-risk group, defined as having
no myometrial invasion, Grade I endometrioid histology, and
no intraperitoneal disease [23]. Mariani et al confirmed a low-
risk group with Grade I to II endometrioid histology, a depth
of invasion of 50%, and tumor size of 2cm; only 5% of
the group had lymph node metastasis [24].They concluded
that lymphadenectomy does not benefit patients in the low-
risk group (the so-called Mayo criteria). Milam et al also
demonstrated that these criteria led to a rate of nodal
metastasis of only 0.8% in the low-risk group of the Mayo
criteria [25]. However, all of these criteria depend on surgi-
copathologic findings. We need prior informed consent
procedures regarding implementation of lymphadenectomybefore surgery, but these criteria are not available in the
pre-operative settings of clinical practice. We proposed a low-
risk group with Grade I to II endometrioid histology by
endometrial biopsy, volume index of 36 by MRI, and low
CA125 level (70 U/mL for patients aged <50 years and
28 U/mL for patients aged 50 years) before surgery; only
2.1% of the group had lymph node metastasis at the assumed
prevalence of nodal metastasis of 10% [26]. Kang et al
confirmed a low-risk group with endometrioid histology by
endometrial biopsy, less than half myometrial invasion and no
extension beyond corpus and no enlarged lymph nodes by
MRI, and CA125 level of 35 before surgery; only 1.3% of
the group had lymph node metastasis at the assumed preva-
lence of nodal metastasis of 10% [27]. These criteria not only
give patients information required for treatment decision-
making but also present suitable eligibility in a clinical
study to assess the therapeutic effect of lymphadenectomy. In
the future, surgical treatment of endometrial cancer will be
followed by an individualized (tailor-made) progression
through scrutiny of clinical trials. Appropriate application of
surgical procedures requires appropriate pre-operative risk
assessment. A worldwide consensus regarding preoperative
risk assessment should be established as soon as possible.
The second prerequisite for clinical trials to assess the
therapeutic role of lymphadenectomy: Procedural
classification of lymphadenectomy
In the TNM classification of malignant tumors developed
by the Union for International Cancer Control (UICC),
regional lymph nodes of endometrial cancer must be pelvic
Fig. 1. Distribution of affected nodes in Stage IIIC endometrial cancer. PAN ¼ para-aortic node; PLN ¼ pelvic node.
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reports about autopsy series, 61% of the patients had para-
aortic node metastasis; para-aortic nodes and interiliac nodes
were the most frequent sites susceptible to metastasis [29].
GOG #33 showed that 18% and 15% of patients with deep
myometrial invasion had pelvic node metastasis and para-
aortic node metastasis, respectively [23]. Previous reports
revealed that 57e73% of patients with pelvic node metastasis
had para-aortic node metastasis [30e33].
According to Fig. 1, >80% and nearly 70% of lymph node
metastases in endometrial cancer are found in the pelvic area
and the para-aortic area, respectively. From the viewpoint of
the diagnostic role of lymphadenectomy, pelvic lymphade-
nectomy can detect >80% of all the affected nodes. From the
viewpoint of the therapeutic role of lymphadenectomy, how-
ever, pelvic lymphadenectomy would leave >60% of all the
affected nodes behind and end in incomplete surgery.
Para-aortic nodes are divided into two sections: (1) an area
between the inferior mesenteric artery and the renal vein
(high para-aortic nodes); and (2), another area between the
bifurcation of aorta and the inferior mesenteric artery (lowFig. 2. Metastatic rate of para-aortic nodes above the inferior mesenteric artery
in Stage IIIC2 endometrial cancer.para-aortic nodes). Some sentinel node mapping studies in
endometrial cancer showed that more than half of para-aortic
nodes identified as sentinel were located above the inferior
mesenteric artery [34,35]. In 1997, Hirahatake et al showed
that 64% of patients with para-aortic lymph node metastasis
harbor disease at the high para-aortic nodes [36]. Other re-
searchers showed that 54e77% of patients with para-aortic
node metastasis harbor disease at the high para-aortic nodes
(Fig. 2).
The eligibility requirements for lymphadenectomy, extent
of lymphadenectomy, and procedure standardization should be
clarified on the discussion about a therapeutic role of lym-
phadenectomy. We are proposing a classification of procedure
by extent of lymphadenectomy and degree of thoroughness in
removal (Table 2). The extent of the surgical field would be
defined as pelvic area alone or combined pelvic and para-
aortic area. Degree of thoroughness in removal would be
defined as removal of only suspicious nodes, selective
dissection, or systematic dissection. Although a certain level
of variation is unavoidable on the clinical practice, a minimal
standardization of procedure is desired in order to assess the
therapeutic role of lymphadenectomy in a prospective
comparative trial. The number of lymph nodes harvestedTable 2
Level of retroperitoneal lymph node dissection in gynecological cancer.
Level Extent and procedure
0 No surgical exploration of lymph nodes
1 Removal of only suspicious nodes in the pelvic area (1A) or pelvic
and para-aortic area (1B)
2 Sampling (2A) or systematic dissection (2B) of pelvic nodes
3 Sampling (2A) or systematic dissection (2B) of pelvic and para-
aortic nodes
3-Low Upper limit of para-aortic node dissection is inferior mesenteric
artery (low para-aortic lymphadenectomy)
3-High Upper limit of para-aortic node dissection is left renal vein and
base of right ovarian vein/right renal vein (high para-aortic
lymphadenectomy)
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Considering previous literature, the number of lymph nodes
harvested that promotes improvement of survival in endome-
trial cancer would be not less than 10. The median [inter-
quartile range (IQR)] number of pelvic lymph nodes harvested
in the SEPAL study were 34 (21e42) in the pelvic lympha-
denectomy alone group and 59 (46e73) in the pelvic and para-
aortic lymphadenectomy group. The median (IQR) number of
para-aortic lymph nodes harvested in the SEPAL study was 23
(16e30) in the pelvic and para-aortic lymphadenectomy group
[18].
RCTs in surgery: Limitations and counter-proposal
Limitations of the SEPAL study derive from the retro-
spective design. Thus, a therapeutic effect of para-aortic
lymphadenectomy should be prospectively validated. How-
ever, is it possible to conduct a prospective RCT to validate
that issue? RCTs must be internally valid, but the results of
each study are relevant to just a definable group of patients in a
particular setting. Namely, RCTs must be externally less valid
[37,38]. Special difficulties are presented in RCTs for surgical
procedures. The recruitment issue is closely related to success
or failure of a randomized surgical trial. It is a threat to
external validity, which is almost a synonym of generaliz-
ability. Many studies have been conducted by dividing the
issues into patients’ reasons and physicians’ reasons [39e49].
Typical patients’ reasons for declining to participate in RCTs
are preference for one form of treatment [40,41], disagreement
with the idea of randomization [41e43], desire to be involved
in decision making [43,44], and insurance coverage [39]. On
the other hand, typical physicians’ reasons for nonentry of
eligible patients into RCTs are preference for one form of
treatment [41], negative impact on the doctorepatient rela-
tionship [40,45,46], time constraints [40,41], lack of staff and
training [40], difficulty with informed consent [46], feelings of
personal responsibility [46], risk of recurrence [47], priorities
of individual care [48], and incentives [49]. Some factors are
related to each other and are not independent. Time constraints
and lack of staff may be almost synonymous with additional
workload. Feelings of personal responsibility, risk of recur-
rence, and priorities of individual care may be batched
together as an ethical issue. Abraham et al demonstrated that a
preference for one form of surgery by the patient or the sur-
geon was the most common reason for nonentry of eligible
patients [41].
Non-participation of experienced surgeons is a major
problem. When there is a RCT in which pelvic lymphade-
nectomy versus combined pelvic and para-aortic lymphade-
nectomy is compared for patients with high-risk endometrial
cancer, some physicians would not participate in this trial
because they would think highly of the effectiveness of
para-aortic lymphadenectomy and would feel uneasy about
performing pelvic lymphadenectomy alone. Experienced
surgeons tend to be familiar with para-aortic lymphadenec-
tomy and its benefits and may decline participation in such a
RCTs due to an ethical dilemma. Conversely, surgeons withlimited experience may be assigned the task of performing
para-aortic lymphadenectomy, and the desired outcome may
not be achieved due to inadequate experience of the doctor.
Both scenarios give rise to a situation in which quality control
of treatment might be reduced in the para-aortic lymphade-
nectomy group. A prospective randomized design in surgical
treatment for high-risk cancer patients would inevitably be
involved in a selection bias if surgeons can predict which
procedure should be more effective. From that viewpoint, a
high-risk group in malignant disease is not suitable for a
randomized surgical trial.
A prospective cohort study may be the most reasonable
method for assessing the therapeutic significance of lympha-
denectomy for high-risk patients. When a small number of
institutions are selected for two different cohorts characterized
by respective surgical intervention, a prescribed surgery is
coherently performed in each cohort, and a common adjuvant
treatment is used in both cohorts, such an observational study
would have an advantage over a prospective randomized study
in that it would promote homogenization of intervention which
eliminates bias. This is because surgeons can perform a sur-
gery without being influenced by random order and then
nonparticipation of surgeons, especially experienced surgeons,
would decrease. Some high-level journals have demonstrated
that results of well-designed observational studies can be
reliable and bear comparison with those of RCTs [50,51]. This
may be the time to reconsider the significance of cohort
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